Company / R&D Expense
Opus Genetics, Inc. R&D Expense History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$26.9M
FY2025
5-year range
$6.6M / $26.9M
FY2021-FY2025
Trend
+52.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $14M to $27M over the past 2 years.
Based on SEC 10-K filings.
$27M in FY2025 with a 3-year CAGR of +21.0%.
Improved from $14M to $27M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +21.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +21.0%, indicating consistent growth.
- In FY2025, r&d expense increased 52.1% year-over-year.
- Lowest r&d expense in the period was in FY2011.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $26.9M | +52.1% |
| FY2024 | $17.7M | +23.0% |
| FY2023 | $14.4M | -5.4% |
| FY2022 | $15.2M | +128.2% |
| FY2021 | $6.6M | +95.9% |
| FY2013 | $3.4M | +6.8% |
| FY2011 | $3.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026